PHARMA CONSULT
0782.498.109 · rovalta.com · 08/11/2026
PHARMA CONSULT
Financial year 2024 · Closed on 31/12/2024
Overview
Identity
Source · BCE/KBOPHARMA CONSULT is a Private limited company incorporated in 2022. Its main activity is: Public relations and communication activities. Its registered office is in Brugelette.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0782.498.109
- Incorporation
- 22/02/2022
- Legal form
- Private limited company
- Registered office
- Chasse Royale(A) 1bis
7941 Brugelette · Wallonie - Contributed capital
- 2 500,00 €
- Latest accounts
- 31/12/2024
Financials
Source · NBB, 3 filingsTrend over 3 financial years
| 2024 | 2023 | 2022 | |||
|---|---|---|---|---|---|
| Income statement | |||||
| Gross margin | 104,8 k € | +39.3% | 75,3 k € | -65.3% | 217,1 k € |
| EBITDA | 102,6 k € | +345% | 23,1 k € | -89.2% | 213,6 k € |
| Operating result | 102,4 k € | +346% | 23 k € | -89.2% | 212,9 k € |
| Net result | 79,2 k € | +373% | 16,7 k € | -89.7% | 163,1 k € |
| Balance sheet | |||||
| Equity | 261,6 k € | +43.4% | 182,4 k € | +10.1% | 165,6 k € |
| Total assets | 371,3 k € | +43.9% | 258,1 k € | +8.3% | 238,3 k € |
| Cash | 24,8 k € | -30.5% | 35,7 k € | +27.5% | 28 k € |
| Debts | 109,7 k € | +45.0% | 75,7 k € | +4.1% | 72,7 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20241 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Jean-Marc RASSE | Mandate |
Financials
Full financial information
Source · NBB| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 22/02/2022 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 |
| Length of the financial year | 12 months | 12 months | 11 months |
| Filing date | 15/09/2025 | 28/10/2024 | 18/07/2024 |
| General meeting | 18/08/2025 | 07/10/2024 | 21/06/2024 |
| Currency of the financial year | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 3 filingsValuation
Indicative valuation
As an indication, this company is worth
between 250 k€ and 500 k€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20241 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Jean-Marc RASSE | Mandate |
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Other24/02/2022RUBRIQUE CONSTITUTION (NOUVELLE PERSONNE MORALE, OUVERTURE SUCCURSALE, ETC...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
Source · CBE, NBB annual accountsRegistered offices
Source · NBB annual accounts, CBE| Registered address | Period | Source |
|---|---|---|
| Chasse Royale(A) 1bis, 7941 AttreCurrent | accounts 2022 → 2024 | Accounts 2024 · 2025-00493860 |
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| PHARMA CONSULTCurrent | accounts 2022 → 2024 | Accounts 2024 · 2025-00493860 |
Events
- 2024Annual accounts 202479,2 k €↑
- 2023Annual accounts 202316,7 k €↓
- 2022Annual accounts 2022163,1 k €
- 22/02/2022IncorporationPrivate limited company